We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+22.34%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$307M
AUM Growth
-$14.5M
Cap. Flow
-$55.8M
Cap. Flow %
-18.15%
Top 10 Hldgs %
77.46%
Holding
48
New
4
Increased
17
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
OMER icon
Omeros
OMER
+$18.4M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$5.17M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.68M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$3.58M
5
KITE
Kite Pharma, Inc.
KITE
+$3.06M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$33.5M
2
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$15.3M
3
ARWR icon
Arrowhead Research
ARWR
+$12.1M
4
BLUE
bluebird bio
BLUE
+$11.3M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$5.46M

Sector Composition

Rank Sector Weight
1 Healthcare 79.43%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
1
Alnylam Pharmaceuticals
ALNY
$36.3B
$54M 17.56%
573,361
+39,701
+7% +$3.68M
LJPC
2
DELISTED
La Jolla Pharmaceutical Company
LJPC
$29.3M 9.53%
1,084,416
+4,085
+0.4% +$111K
OMER icon
3
Omeros
OMER
$709M
$28.6M 9.31%
1,819,341
+1,329,341
+271% +$18.4M
KITE
4
DELISTED
Kite Pharma, Inc.
KITE
$25.8M 8.4%
418,935
+43,459
+12% +$3.06M
DRNA
5
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$23.9M 7.77%
2,012,662
+7,424
+0.4% +$84.9K
ACHN
6
DELISTED
Achillion Pharmaceuticals
ACHN
$21.5M 6.98%
1,988,914
-600,904
-23% -$5.46M
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$2.37B
$20.7M 6.75%
2,010,501
-217,705
-10% -$2.16M
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$12.2M 3.96%
385,456
-96,613
-20% -$3.41M
ATRA icon
9
Atara Biotherapeutics
ATRA
$71.2M
$11.5M 3.73%
17,357
+6,837
+65% +$5.17M
FPRX
10
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$10.7M 3.47%
257,236
-456,718
-64% -$15.3M
AGEN
11
Agenus
AGEN
$249M
$10.1M 3.27%
112,826
+6,639
+6% +$607K
CLDX icon
12
Celldex Therapeutics
CLDX
$2.77B
$9.99M 3.25%
42,483
-5,432
-11% -$1.18M
SSRG
13
DELISTED
SYMMETRY SURGICAL INC COMMON STK
SSRG
$8.09M 2.63%
879,623
+72,181
+9% +$643K
BMY icon
14
Bristol-Myers Squibb
BMY
$127B
$7.55M 2.45%
109,701
+7,276
+7% +$481K
CORI
15
DELISTED
Corium International, Inc.
CORI
$6.04M 1.97%
743,865
+168,653
+29% +$1.33M
GBT
16
DELISTED
Global Blood Therapeutics, Inc.
GBT
$5.66M 1.84%
175,156
+82,757
+90% +$3.58M
DYAX
17
DELISTED
DYAX CORPORATION
DYAX
$4.36M 1.42%
115,795
+437
+0.4% +$14K
RGNX icon
18
Regenxbio
RGNX
$623M
$3.67M 1.2%
221,326
+16,832
+8% +$334K
LPCN icon
19
Lipocine
LPCN
$17.1M
$2.85M 0.93%
12,971
+471
+4% +$98.8K
AXDX
20
DELISTED
Accelerate Diagnostics
AXDX
$2.31M 0.75%
+10,747
New +$1.96M
IVTY
21
DELISTED
Invuity, Inc
IVTY
$1.79M 0.58%
202,808
+27,808
+16% +$330K
CYTR
22
DELISTED
CytRx Corp
CYTR
$1.25M 0.41%
78,429
+2,851
+4% +$48.9K
MASI
23
DELISTED
Masimo
MASI
$1.07M 0.35%
25,900
– –
ANIK icon
24
Anika Therapeutics
ANIK
$199M
$1.05M 0.34%
+27,500
New +$1.05M
MDRX
25
DELISTED
Veradigm Inc. Common Stock
MDRX
$738K 0.24%
48,000
– –
1
2

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q4 2015 Portfolio in Review

As of Q4 2015, RTW Investments held 48 positions worth $307M, down 4.5% from $322M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

RTW Investments withdrew a net $55.8M in Q4 2015, closing 10 positions and reducing 6 holdings. Its most notable exit was Incyte, an estimated $33.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 84% a quarter earlier, followed by Financials.

Against the trend, RTW Investments opened a new position in Accelerate Diagnostics worth $2.31M.

  • RTW Investments's largest Q4 2015 buy was Accelerate Diagnostics: 10,747 shares worth $2.31M.
  • RTW Investments added most to Omeros in Q4 2015, an estimated $18.4M increase.
  • RTW Investments's biggest Q4 2015 reduction was Five Prime Therapeutics, Inc., cutting an estimated $15.3M.
  • RTW Investments fully exited Incyte in Q4 2015, selling an estimated $33.5M.
  • RTW Investments's ten largest holdings make up 77% of its $307M portfolio in Q4 2015.
  • RTW Investments opened 4 new positions and closed 10 in Q4 2015.
  • RTW Investments's portfolio value fell 4.5% quarter-over-quarter to $307M.

Based on RTW Investments's 13F filing for Q4 2015, filed 16 Feb 2016.